Trials / Completed
CompletedNCT01522521
Study of AK156 in Primary Osteoporosis Patients
Phase 3 Study of AK156 in Primary Osteoporosis Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 600 (estimated)
- Sponsor
- Asahi Kasei Therapeutics Corporation · Industry
- Sex
- All
- Age
- 65 Years – 89 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the efficacy and safety of AK156 in Japanese patients with primary osteoporosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK156 | zoledronic acid (i.v.)/year + daily calcium and vitamin D for 2 years |
| DRUG | Placebo | placebo (i.v.)/year + daily calcium and vitamin D for 2 years |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2015-01-01
- Completion
- 2015-01-01
- First posted
- 2012-01-31
- Last updated
- 2015-10-02
Locations
20 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01522521. Inclusion in this directory is not an endorsement.